Published in Cancer Weekly, November 4th, 1996
Due to the lack of an effective therapy against primary brain tumors, investigators have been exploring novel experimental approaches that involve the use of vectors and recombinant viruses. These therapeutic approaches have been both indirect, whereby vectors are used to transfect therapeutic genes, and direct, whereby direct cell killing is mediated by an introduced virus.
Samita S. Andreansky et al. evaluated a genetically engineered HSV vector as an experimental approach to directly...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.